These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 27803803)

  • 1. Group B
    Kobayashi M; Vekemans J; Baker CJ; Ratner AJ; Le Doare K; Schrag SJ
    F1000Res; 2016; 5():2355. PubMed ID: 27803803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.
    Kobayashi M; Schrag SJ; Alderson MR; Madhi SA; Baker CJ; Sobanjo-Ter Meulen A; Kaslow DC; Smith PG; Moorthy VS; Vekemans J
    Vaccine; 2019 Nov; 37(50):7307-7314. PubMed ID: 28017431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa.
    Kim SY; Russell LB; Park J; Verani JR; Madhi SA; Cutland CL; Schrag SJ; Sinha A
    Vaccine; 2014 Apr; 32(17):1954-63. PubMed ID: 24530145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States.
    Kim SY; Nguyen C; Russell LB; Tomczyk S; Abdul-Hakeem F; Schrag SJ; Verani JR; Sinha A
    Vaccine; 2017 Oct; 35(45):6238-6247. PubMed ID: 28951085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group B streptococcus colonization in pregnancy and neonatal outcomes: a three-year monocentric retrospective study during and after the COVID-19 pandemic.
    Serra G; Scalzo LL; Giordano M; Giuffrè M; Trupiano P; Venezia R; Corsello G
    Ital J Pediatr; 2024 Sep; 50(1):175. PubMed ID: 39267078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.
    Madhi SA; Dangor Z; Heath PT; Schrag S; Izu A; Sobanjo-Ter Meulen A; Dull PM
    Vaccine; 2013 Aug; 31 Suppl 4():D52-7. PubMed ID: 23973347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches.
    Absalon J; Simon R; Radley D; Giardina PC; Koury K; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2022 Dec; 18(1):2037350. PubMed ID: 35240933
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Limaye RJ; Singh P; Fesshaye B; Lee C; Schue J; Karron RA
    Hum Vaccin Immunother; 2024 Dec; 20(1):2314826. PubMed ID: 38345050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of maternal immunization against neonatal invasive Group B Streptococcus in the Netherlands.
    Hahn BA; de Gier B; van Kassel MN; Bijlsma MW; van Leeuwen E; Wouters MGAJ; van der Ende A; van de Beek D; Wallinga J; Hahné SJM; Jan van Hoek A
    Vaccine; 2021 May; 39(21):2876-2885. PubMed ID: 33895018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study.
    Carreras-Abad C; Cochet M; Hall T; Ramkhelawon L; Khalil A; Peregrine E; Vinayakarao L; Sivarajan S; Hamid R; Planche T; Sheridan E; Winchester S; Plumb J; Djennad A; Andrews N; Le Doare K; Heath P
    Health Technol Assess; 2019 Dec; 23(67):1-40. PubMed ID: 31855555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness.
    Procter SR; Gonçalves BP; Paul P; Chandna J; Seedat F; Koukounari A; Hutubessy R; Trotter C; Lawn JE; Jit M
    PLoS Med; 2023 Mar; 20(3):e1004068. PubMed ID: 36917564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Italian arm of the PREPARE study: an international project to evaluate and license a maternal vaccine against group B streptococcus.
    Berardi A; Cassetti T; Creti R; Vocale C; Ambretti S; Sarti M; Facchinetti F; Cose S; ; Heath P; Le Doare K
    Ital J Pediatr; 2020 Oct; 46(1):160. PubMed ID: 33115542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group B Streptococcus: Trials and Tribulations.
    Davies HG; Carreras-Abad C; Le Doare K; Heath PT
    Pediatr Infect Dis J; 2019 Jun; 38(6S Suppl 1):S72-S76. PubMed ID: 31205250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine.
    Schrag SJ; Verani JR
    Vaccine; 2013 Aug; 31 Suppl 4():D20-6. PubMed ID: 23219695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 20 million pregnant women with group B streptococcus carriage: consequences, challenges, and opportunities for prevention.
    Paul P; Gonçalves BP; Le Doare K; Lawn JE
    Curr Opin Pediatr; 2023 Apr; 35(2):223-230. PubMed ID: 36749143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa.
    Russell LB; Kim SY; Cosgriff B; Pentakota SR; Schrag SJ; Sobanjo-Ter Meulen A; Verani JR; Sinha A
    Vaccine; 2017 Dec; 35(49 Pt B):6905-6914. PubMed ID: 29129451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in reducing group B Streptococcus disease in African settings.
    Nishihara Y; Dangor Z; French N; Madhi S; Heyderman R
    Arch Dis Child; 2017 Jan; 102(1):72-77. PubMed ID: 27831912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of maternal vaccination against Group B streptococcus in Japan.
    Sorano S; Procter SR; Seale AC
    Vaccine X; 2023 Aug; 14():100332. PubMed ID: 37441365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status of vaccine research and development of vaccines for GBS.
    Heath PT
    Vaccine; 2016 Jun; 34(26):2876-2879. PubMed ID: 26988258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study.
    Giorgakoudi K; O'Sullivan C; Heath PT; Ladhani S; Lamagni T; Ramsay M; Al-Janabi H; Trotter C
    Vaccine; 2018 Nov; 36(46):7033-7042. PubMed ID: 30293765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.